Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
3(25%)
Results Posted
40%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
3
25%
Ph phase_3
1
8%
Ph phase_4
2
17%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

3

trials recruiting

Total Trials

12

all time

Status Distribution
Active(5)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Recruiting3
Not yet recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
3
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 31 (14.3%)
Phase 42 (28.6%)

Trials by Status

completed542%
not_yet_recruiting217%
terminated18%
unknown18%
recruiting325%

Recent Activity

3 active trials
Showing 5 of 12
completed

Lipids, Inflammation, and CV Risk in RA

NCT02714881
not_yet_recruitingphase_4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
recruitingphase_2

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

NCT04991025
completedphase_2

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438
not_yet_recruitingphase_2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT02714881

Lipids, Inflammation, and CV Risk in RA

Completed
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT04991025Phase 2

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Recruiting
NCT06028438Phase 2

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Completed
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not Yet Recruiting
NCT03414502Phase 3

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting
NCT04725422

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting
NCT02120807Phase 1

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Completed
NCT03955861

Ultrasound Enthesitis Response in Psoriatic Arthritis

Completed
NCT01582568

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Terminated
NCT01098201

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Completed
NCT02132234Phase 4

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12